Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy

Hye-Young KIM; Jeong-Hee KANG; Hyun-Jo YOUN; Hyang-Sook SO; Chi-Eun SONG; Seo-Young CHAE; Sung-Hoo JUNG; Sung-Reul KIM; Ji-Young KIM; Hye-Young KIM; Jeong-Hee KANG; Hyun-Jo YOUN; Hyang-Sook SO; Chi-Eun SONG; Seo-Young CHAE; Sung-Hoo JUNG; Sung-Reul KIM; Ji-Young KIM.
Journal of Korean Academy of Nursing ; : 735-742, 2014.
Artículo en Ko | WPRIM | ID: wpr-42237

Documentos relacionados

  1. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy-induced peripheral neuropathy.
  2. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
  3. IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS.
  4. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
  5. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy.
  6. Therapeutic strategies for cancer treatment related peripheral neuropathies.
  7. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
  8. Living with chemotherapy-induced peripheral neuropathy: a nested qualitative study.
  9. Exploring Patients' Understanding of Chemotherapy-Induced Peripheral Neuropathy.
  10. Determinants of cancer drug pricing and how to overcome the cancer premium.